333 related articles for article (PubMed ID: 27196083)
1. Validation of Novel Biomarkers for Prostate Cancer Progression by the Combination of Bioinformatics, Clinical and Functional Studies.
Alinezhad S; Väänänen RM; Mattsson J; Li Y; Tallgrén T; Tong Ochoa N; Bjartell A; Åkerfelt M; Taimen P; Boström PJ; Pettersson K; Nees M
PLoS One; 2016; 11(5):e0155901. PubMed ID: 27196083
[TBL] [Abstract][Full Text] [Related]
2. Differentially expressed androgen-regulated genes in androgen-sensitive tissues reveal potential biomarkers of early prostate cancer.
Altintas DM; Allioli N; Decaussin M; de Bernard S; Ruffion A; Samarut J; Vlaeminck-Guillem V
PLoS One; 2013; 8(6):e66278. PubMed ID: 23840433
[TBL] [Abstract][Full Text] [Related]
3. Random forest-based modelling to detect biomarkers for prostate cancer progression.
Toth R; Schiffmann H; Hube-Magg C; Büscheck F; Höflmayer D; Weidemann S; Lebok P; Fraune C; Minner S; Schlomm T; Sauter G; Plass C; Assenov Y; Simon R; Meiners J; Gerhäuser C
Clin Epigenetics; 2019 Oct; 11(1):148. PubMed ID: 31640781
[TBL] [Abstract][Full Text] [Related]
4. Stratification of aggressive prostate cancer from indolent disease-Prospective controlled trial utilizing expression of 11 genes in apparently benign tissue.
Alinezhad S; Väänänen RM; Tallgrén T; Perez IM; Jambor I; Aronen H; Kähkönen E; Ettala O; Syvänen K; Nees M; Kallajoki M; Taimen P; Boström PJ; Pettersson K
Urol Oncol; 2016 Jun; 34(6):255.e15-22. PubMed ID: 26857646
[TBL] [Abstract][Full Text] [Related]
5. Klf4 transcription factor is expressed in the cytoplasm of prostate cancer cells.
Le Magnen C; Bubendorf L; Ruiz C; Zlobec I; Bachmann A; Heberer M; Spagnoli GC; Wyler S; Mengus C
Eur J Cancer; 2013 Mar; 49(4):955-63. PubMed ID: 23089465
[TBL] [Abstract][Full Text] [Related]
6. Down-regulation of protein kinase, DNA-activated, catalytic polypeptide attenuates tumor progression and is an independent prognostic predictor of survival in prostate cancer.
Zhang X; Wang Y; Ning Y
Urol Oncol; 2017 Mar; 35(3):111.e15-111.e23. PubMed ID: 27856181
[TBL] [Abstract][Full Text] [Related]
7. Epigenetic silencing of MEIS2 in prostate cancer recurrence.
Nørgaard M; Haldrup C; Bjerre MT; Høyer S; Ulhøi B; Borre M; Sørensen KD
Clin Epigenetics; 2019 Oct; 11(1):147. PubMed ID: 31640805
[TBL] [Abstract][Full Text] [Related]
8. The expression and clinical significance of GTP-binding RAS-like 3 (ARHI) and microRNA 221 and 222 in prostate cancer.
Lin D; Cui F; Bu Q; Yan C
J Int Med Res; 2011; 39(5):1870-5. PubMed ID: 22117988
[TBL] [Abstract][Full Text] [Related]
9. Detection of High-grade Prostate Cancer Using a Urinary Molecular Biomarker-Based Risk Score.
Van Neste L; Hendriks RJ; Dijkstra S; Trooskens G; Cornel EB; Jannink SA; de Jong H; Hessels D; Smit FP; Melchers WJ; Leyten GH; de Reijke TM; Vergunst H; Kil P; Knipscheer BC; Hulsbergen-van de Kaa CA; Mulders PF; van Oort IM; Van Criekinge W; Schalken JA
Eur Urol; 2016 Nov; 70(5):740-748. PubMed ID: 27108162
[TBL] [Abstract][Full Text] [Related]
10. ING3 is associated with increased cell invasion and lethal outcome in ERG-negative prostate cancer patients.
Almami A; Hegazy SA; Nabbi A; Alshalalfa M; Salman A; Abou-Ouf H; Riabowol K; Bismar TA
Tumour Biol; 2016 Jul; 37(7):9731-8. PubMed ID: 26803516
[TBL] [Abstract][Full Text] [Related]
11. RAB27A, RAB27B and VPS36 are downregulated in advanced prostate cancer and show functional relevance in prostate cancer cells.
Worst TS; Meyer Y; Gottschalt M; Weis CA; von Hardenberg J; Frank C; Steidler A; Michel MS; Erben P
Int J Oncol; 2017 Mar; 50(3):920-932. PubMed ID: 28197629
[TBL] [Abstract][Full Text] [Related]
12. Candidate diagnostic miRNAs that can detect cancer in prostate biopsy.
Paziewska A; Mikula M; Dabrowska M; Kulecka M; Goryca K; Antoniewicz A; Dobruch J; Borowka A; Rutkowski P; Ostrowski J
Prostate; 2018 Feb; 78(3):178-185. PubMed ID: 29226351
[TBL] [Abstract][Full Text] [Related]
13. The role of HOXC6 in prostate cancer development.
Hamid AR; Hoogland AM; Smit F; Jannink S; van Rijt-van de Westerlo C; Jansen CF; van Leenders GJ; Verhaegh GW; Schalken JA
Prostate; 2015 Dec; 75(16):1868-76. PubMed ID: 26310814
[TBL] [Abstract][Full Text] [Related]
14. ACSS3 represses prostate cancer progression through downregulating lipid droplet-associated protein PLIN3.
Zhou L; Song Z; Hu J; Liu L; Hou Y; Zhang X; Yang X; Chen K
Theranostics; 2021; 11(2):841-860. PubMed ID: 33391508
[TBL] [Abstract][Full Text] [Related]
15. Phospholipase PLA2G7, associated with aggressive prostate cancer, promotes prostate cancer cell migration and invasion and is inhibited by statins.
Vainio P; Lehtinen L; Mirtti T; Hilvo M; Seppänen-Laakso T; Virtanen J; Sankila A; Nordling S; Lundin J; Rannikko A; Orešič M; Kallioniemi O; Iljin K
Oncotarget; 2011 Dec; 2(12):1176-90. PubMed ID: 22202492
[TBL] [Abstract][Full Text] [Related]
16. Ets-1 is implicated in the regulation of androgen co-regulator FHL2 and reveals specificity for migration, but not invasion, of PC3 prostate cancer cells.
Adler D; Langer B; Lindstrot A; Florin A; Bosserhoff A; Buettner R; Wernert N
Oncol Rep; 2011 Apr; 25(4):1125-9. PubMed ID: 21258770
[TBL] [Abstract][Full Text] [Related]
17. Epigenetic disruption of miR-130a promotes prostate cancer by targeting SEC23B and DEPDC1.
Ramalho-Carvalho J; Martins JB; Cekaite L; Sveen A; Torres-Ferreira J; Graça I; Costa-Pinheiro P; Eilertsen IA; Antunes L; Oliveira J; Lothe RA; Henrique R; Jerónimo C
Cancer Lett; 2017 Jan; 385():150-159. PubMed ID: 27984115
[TBL] [Abstract][Full Text] [Related]
18. Specific and redundant activities of ETV1 and ETV4 in prostate cancer aggressiveness revealed by co-overexpression cellular contexts.
Mesquita D; Barros-Silva JD; Santos J; Skotheim RI; Lothe RA; Paulo P; Teixeira MR
Oncotarget; 2015 Mar; 6(7):5217-36. PubMed ID: 25595908
[TBL] [Abstract][Full Text] [Related]
19. Identification of candidate diagnostic and prognostic biomarkers for human prostate cancer: RPL22L1 and RPS21.
Liang Z; Mou Q; Pan Z; Zhang Q; Gao G; Cao Y; Gao Z; Pan Z; Feng W
Med Oncol; 2019 May; 36(6):56. PubMed ID: 31089825
[TBL] [Abstract][Full Text] [Related]
20. MiR-203 down-regulates Rap1A and suppresses cell proliferation, adhesion and invasion in prostate cancer.
Xiang J; Bian C; Wang H; Huang S; Wu D
J Exp Clin Cancer Res; 2015 Jan; 34(1):8. PubMed ID: 25636908
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
